Skip to main content
. 2018 Mar 12;51(1):119–127. doi: 10.4143/crt.2018.019

Table 4.

Systemic treatments after progression

Treatment Irinotecan plus cisplatin (n=173) Etoposide plus cisplatin (n=189)
No systemic treatment 72 (41.6) 73 (38.6)
Etoposide containing regimen 84 (48.6) 9 (4.8)
Irinotecan containing regimen 10 (5.8) 65 (34.4)
Cyclophosphamide+doxorubicin+vincristine 30 (17.3) 26 (13.8)
Topotecan or belotecan 15 (8.7) 39 (20.6)
Paclitaxel 8 (4.6) 11 (5.8)
Ifosfamide 6 (3.5) 5 (2.6)
Others 12 (6.9) 11 (5.8)

Values are presented as number (%).